Zometa (Zoledronic Acid)


Indications and Reactions:

Role Indications Reactions
Secondary
Product Used For Unknown Indication 83.0%
Plasma Cell Myeloma 9.4%
Cerebrovascular Accident 5.7%
Chemotherapy 1.9%
Increased Tendency To Bruise 18.2%
Blood Immunoglobulin G Increased 9.1%
Ear Infection 9.1%
Local Swelling 9.1%
No Therapeutic Response 9.1%
Pain In Extremity 9.1%
Rash Pruritic 9.1%
Renal Impairment 9.1%
Urinary Tract Infection Staphylococcal 9.1%
White Blood Cell Count Decreased 9.1%
Concomitant
Plasma Cell Myeloma 79.1%
Prostate Cancer Metastatic 5.4%
Breast Cancer 3.6%
Hormone Replacement Therapy 2.2%
Thyroid Cancer 2.2%
Product Used For Unknown Indication 1.8%
Bronchial Carcinoma 0.7%
Pain 0.7%
5Q Minus Syndrome 0.4%
Actinic Keratosis 0.4%
Breast Cancer Metastatic 0.4%
Cancer Pain 0.4%
Gouty Arthritis 0.4%
Hypertension 0.4%
Neuroendocrine Carcinoma 0.4%
Prophylaxis Against Gastrointestinal Ulcer 0.4%
Renal Cancer 0.4%
Renal Cell Carcinoma 0.4%
Secondary Acquired Hypogammaglobulinemia 0.4%
Vasculitis 0.4%
White Blood Cell Count Decreased 15.4%
Rash 9.4%
Thrombosis 8.5%
Pneumonia 6.8%
Pyrexia 6.0%
Fatigue 5.1%
Neuropathy Peripheral 5.1%
Vomiting 5.1%
Oedema Peripheral 4.3%
Pancytopenia 4.3%
Deep Vein Thrombosis 3.4%
Nasopharyngitis 3.4%
Pain In Extremity 3.4%
Rash Pruritic 3.4%
Thrombocytopenia 3.4%
Diarrhoea 2.6%
Increased Tendency To Bruise 2.6%
Plasma Cell Myeloma 2.6%
Platelet Count Decreased 2.6%
Pulmonary Embolism 2.6%

Drug Data